
























































































































































































































































































































































































































































































































































































































































































































































































































An	 important	consideration	 for	 space	 flight,	however,	 is	 that	 these	 technologies	could	potentially	
fail,	 yielding	 inaccurate	 results.	 These	 failures	 could	 be	 caused	by	 fibrosis	 around	 the	 devices	 or	













care	 of	 our	 astronauts.	 These	 devices	 are	 proving	 to	 be	 light	 weight,	 safe,	 accurate	 and	 easily	
incorporated	into	existing	systems	such	as	mobile	devices.	
Future	direction	
The	following	points	outline	some	areas	of	further	research	that	are	likely	to	be	of	benefit	for	the	
use	of	the	above	mentioned	technologies	in	space	flight:	
 Determination	of	the	scope	of	medical	treatment	available	on	long	duration	flights	to	drive	
focus	of	specific	molecular	targets.		
 Evaluation	of	the	longevity	of	implantable	devices	
 Evaluation	of	these	technologies	in	microgravity	to	examine	if	function	is	altered	in	space.	
 Evaluation	of	immunological	effects	of	long	term	implantable	devices	in	humans	
 Evaluation	of	the	necessity	of	the	full	scope	of	laboratory	analysis	in	consideration	of	
limited	treatment	options	
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